AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-06-18T00:44:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Recce Pharmaceuticals lands ethics approval for expanded UTI studies
Fri 30 Jun 23, 06:00 PMRecce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
Wed 28 Jun 23, 12:00 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Minority interest | - | - | - | - | - |
| Net income | -13.07742M | -10.98869M | -15.10834M | -5.33681M | -2.84589M |
| Selling general administrative | 4.11M | 2.37M | 6.81M | 1.59M | 1.60M |
| Selling and marketing expenses | 1.12M | 0.99M | 0.70M | - | - |
| Gross profit | - | - | - | - | 0.20M |
| Reconciled depreciation | 0.22M | 0.19M | 0.30M | 0.20M | 0.06M |
| Ebit | -12.90480M | -10.98386M | -13.51126M | -4.27089M | -2.73250M |
| Ebitda | -12.68764M | -10.79619M | -13.21563M | -4.07007M | -2.67641M |
| Depreciation and amortization | 0.22M | 0.19M | 0.30M | 0.20M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -12.90480M | -10.98386M | -13.51126M | -4.27089M | -2.73250M |
| Other operating expenses | 17.24M | 12.60M | 15.20M | 5.26M | 3.31M |
| Interest expense | 0.17M | 0.00242M | 0.00211M | 0.05M | 0.06M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.18M | 0.09M | 0.11M | 0.06M | 0.06M |
| Net interest income | -0.11707M | 0.08M | 0.09M | -0.04585M | -0.04970M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 4.45M | 0.00242M | 1.59M | 1.02M | 0.06M |
| Total revenue | 4.43M | 3.18M | 1.96M | 1.15M | 0.69M |
| Total operating expenses | 17.24M | 12.60M | 15.20M | 5.26M | 3.31M |
| Cost of revenue | - | - | - | - | 0.48M |
| Total other income expense net | 4.28M | -0.00242M | -0.00211M | -0.04585M | -0.05669M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Net income applicable to common shares | -13.07742M | -10.98628M | -13.51337M | -4.31674M | -2.78920M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 6.37M | 2.56M | 12.62M | 21.68M | 3.24M |
| Intangible assets | - | 0.00002M | 0.00003M | 0.00006M | 0.00009M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.56M | 0.16M | 0.42M | 0.06M | 0.02M |
| Total liab | 15.89M | 5.14M | 2.56M | 1.18M | 0.93M |
| Total stockholder equity | -9.52377M | -2.58880M | 10.06M | 20.50M | 2.31M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 10.88M | 3.90M | 1.97M | 0.59M | 0.73M |
| Common stock | 54.84M | 44.11M | 43.97M | 43.30M | 18.47M |
| Capital stock | 54.84M | 44.11M | 43.97M | 43.30M | 18.47M |
| Retained earnings | -70.07587M | -55.53532M | -42.45790M | -31.47162M | -17.95826M |
| Other liab | - | 0.19M | 0.12M | 0.09M | 0.05M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | -0.00000M |
| Cash | 4.21M | 1.56M | 11.58M | 20.87M | 2.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.07M | 4.85M | 2.45M | 1.08M | 0.89M |
| Current deferred revenue | - | -0.14788M | -0.07476M | -0.11259M | -0.08324M |
| Net debt | -3.39613M | -1.31101M | -11.50717M | -20.74609M | -2.59896M |
| Short term debt | 0.22M | 0.15M | 0.07M | 0.11M | 0.08M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.81M | 0.25M | 0.07M | 0.13M | 0.08M |
| Other stockholder equity | - | 8.83M | -1.51042M | -11.82568M | -0.50808M |
| Property plant equipment | - | 0.61M | 0.44M | 0.50M | 0.50M |
| Total current assets | 5.14M | 1.95M | 12.18M | 21.18M | 2.74M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -2.58882M | 10.06M | 20.50M | 2.31M |
| Short term investments | 0.21M | 0.05M | 0.02M | - | - |
| Net receivables | 0.16M | 0.09M | 0.18M | 0.25M | 0.04M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.14M | - | - | - |
| Accounts payable | 3.97M | 0.95M | 0.48M | 0.49M | 0.16M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 5.71M | 8.83M | 8.55M | 8.68M | 1.80M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 18.47M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.00000M | -0.00002M | -0.00003M | -0.00006M | -0.00009M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.23M | 0.61M | 0.44M | 0.50M | 0.50M |
| Capital lease obligations | 0.81M | 0.25M | 0.07M | 0.13M | 0.08M |
| Long term debt total | - | 0.10M | 0.00000M | 0.01M | 0.00000M |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Investments | -0.14189M | -0.03863M | -0.04034M | -0.07601M | -0.00594M |
| Change to liabilities | - | 0.77M | 0.16M | 0.28M | 0.18M |
| Total cashflows from investing activities | - | -0.03863M | -0.04034M | -0.07601M | -0.00594M |
| Net borrowings | - | 2.71M | -0.13917M | -0.17470M | -0.88751M |
| Total cash from financing activities | 16.00M | 2.71M | -0.24050M | 26.12M | 6.09M |
| Change to operating activities | - | -1.01017M | 1.31M | 0.06M | 0.08M |
| Net income | -17.66171M | -13.07742M | -10.98628M | -13.51337M | -4.31674M |
| Change in cash | 2.85M | -10.02036M | -9.29111M | 18.19M | 2.28M |
| Begin period cash flow | 1.56M | 11.58M | 20.87M | 2.68M | 0.40M |
| End period cash flow | 4.42M | 1.56M | 11.58M | 20.87M | 2.68M |
| Total cash from operating activities | -13.00866M | -12.68737M | -9.01026M | -7.85585M | -3.80745M |
| Issuance of capital stock | 11.15M | 0.10M | 0.29M | 28.06M | 6.98M |
| Depreciation | 0.37M | 0.22M | 0.19M | 0.30M | 0.20M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | 1.72M | 1.72M | 1.72M |
| Change to inventory | - | 0.24M | -1.46884M | 0.00000M | -0.25811M |
| Change to account receivables | 0.06M | 0.09M | 0.06M | -0.20412M | -0.00485M |
| Sale purchase of stock | - | - | -1.71867M | -1.71867M | -1.71867M |
| Other cashflows from financing activities | -1.02761M | -0.27450M | -0.52791M | -0.21490M | -0.15011M |
| Change to netincome | - | 0.33M | 0.26M | 5.22M | 0.06M |
| Capital expenditures | 0.14M | 0.04M | 0.04M | 0.08M | 0.00594M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 4.27M | -0.15232M | 1.53M | 0.14M | 0.25M |
| Stock based compensation | 0.02M | 0.33M | 0.26M | 5.22M | 0.06M |
| Other non cash items | 0.39M | -0.09832M | 0.46M | 5.73M | 0.28M |
| Free cash flow | -13.15055M | -12.72600M | -9.05061M | -7.93186M | -3.81339M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| RCE Recce Ltd |
-0.02 6.15% | 0.30 | - | - | 9.62 | 208.12 | -8.4268 | |
| CSL CSL Ltd |
0.82 0.34% | 240.11 | 28.85 | 33.67 | 7.67 | 4.14 | 5.94 | 18.44 |
| TLX Telix Pharmaceuticals Ltd |
0.56 2.20% | 26.07 | 183.21 | 21.01 | 10.96 | 15.11 | 10.80 | 91.38 |
| MSB Mesoblast Ltd |
-0.035 1.92% | 1.79 | - | 454.55 | 414.37 | 3.34 | 67.90 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
0.38 2.96% | 13.23 | 13.00 | 81.97 | 8.10 | 4.86 | 7.25 | 8.80 |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis rapid infusion; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. Recce Pharmaceuticals has strategic partnership with Murdoch Children's Research Institute for development of the Neisseria gonorrhoeae, Mycobacterium abscessus, and Escherichia coli clinical trials; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Salesforce Tower, Sydney, NSW, Australia, 2000
| Name | Title | Year Born |
|---|---|---|
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Exec. Director | NA |
| Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) | Chief Scientific Director & Exec. Director | NA |
| Dr. Justin Ward | Principal Quality Chemist & Exec. Director | NA |
| Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing | NA |
| Mr. Justin Reynolds | Chief Financial Officer | NA |
| Thomas Jarrett | Operations Mang. | NA |
| Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing | NA |
| Ms. Maggie Niewidok | Company Sec. | NA |
| Dr. John K. A. Prendergast Ph.D. | Executive Chairman of the Board | 1954 |
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Executive Director | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...